HTC
VRTX icon

Haverford Trust Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Haverford Trust Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$296K Sell
663
-77
-10% -$35.9K ﹤0.01% 367
2025
Q4 		$335K Buy
+740
New +$319K ﹤0.01% 347
2025
Q3 		– Sell
-463
Closed -$206K – 417
2025
Q2 		$206K Buy
+463
New +$213K ﹤0.01% 396

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Haverford Trust Company's VRTX Position: Q1 2026 in Review

Haverford Trust Company reduced its Vertex Pharmaceuticals (VRTX) stake by 10% in Q1 2026, selling an estimated $35.9K and leaving 663 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #367.

Haverford Trust Company first reported a position in VRTX in Q2 2025 and has held it in 3 quarters since. The position peaked at $335K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Haverford Trust Company held 663 shares of Vertex Pharmaceuticals worth $296K as of Q1 2026.
  • Haverford Trust Company sold 77 Vertex Pharmaceuticals shares in Q1 2026, an estimated $35.9K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Haverford Trust Company's portfolio in Q1 2026, its #367 holding.
  • Haverford Trust Company first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • Haverford Trust Company's Vertex Pharmaceuticals position peaked at $335K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Haverford Trust Company's 13F filing for Q1 2026, filed 11 May 2026.